[go: up one dir, main page]

MX2018000891A - Composiciones y metodos para formas de liofilos de nanoparticulas. - Google Patents

Composiciones y metodos para formas de liofilos de nanoparticulas.

Info

Publication number
MX2018000891A
MX2018000891A MX2018000891A MX2018000891A MX2018000891A MX 2018000891 A MX2018000891 A MX 2018000891A MX 2018000891 A MX2018000891 A MX 2018000891A MX 2018000891 A MX2018000891 A MX 2018000891A MX 2018000891 A MX2018000891 A MX 2018000891A
Authority
MX
Mexico
Prior art keywords
nucleic acid
acid agents
active nucleic
compositions
liophiles
Prior art date
Application number
MX2018000891A
Other languages
English (en)
Other versions
MX373982B (es
Inventor
Liu Dong
Ying Wenbin
Adami Roger
Wang Yuwei
Yin Haiqing
Wang Liping
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of MX2018000891A publication Critical patent/MX2018000891A/es
Publication of MX373982B publication Critical patent/MX373982B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención proporciona composiciones para elaborar un liófilo sólido de uno o más agentes activos de ácido nucleico, el cual puede reconstituirse como producto farmacológico. La composición puede incluir una suspensión acuosa de nanopartículas lipídicas en una solución farmacéuticamente aceptable, en donde las nanopartículas lipídicas encapsulan uno o más agentes activos de ácido nucleico, un compuesto de dextrina y un compuesto tipo sacárido. Los agentes activos de ácido nucleico pueden ser moléculas de RNAi capaces de mediar la interferencia por RNA, así como otros RNA y oligonucleótidos.
MX2018000891A 2015-07-22 2016-07-22 Composiciones y metodos para formas de liofilos de nanoparticulas. MX373982B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195356P 2015-07-22 2015-07-22
PCT/US2016/043537 WO2017015552A1 (en) 2015-07-22 2016-07-22 Compositions and methods for nanoparticle lyophile forms

Publications (2)

Publication Number Publication Date
MX2018000891A true MX2018000891A (es) 2018-06-11
MX373982B MX373982B (es) 2020-07-15

Family

ID=57834582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000891A MX373982B (es) 2015-07-22 2016-07-22 Composiciones y metodos para formas de liofilos de nanoparticulas.

Country Status (23)

Country Link
US (3) US10300018B2 (es)
EP (1) EP3324932B1 (es)
JP (2) JP6875373B2 (es)
KR (1) KR102716928B1 (es)
CN (2) CN113679689B (es)
AU (1) AU2016297153B2 (es)
CA (1) CA2992849C (es)
CY (1) CY1123984T1 (es)
DK (1) DK3324932T3 (es)
EA (1) EA035761B1 (es)
ES (1) ES2862191T3 (es)
HR (1) HRP20210523T1 (es)
HU (1) HUE053990T2 (es)
IL (2) IL288342B2 (es)
LT (1) LT3324932T (es)
MX (1) MX373982B (es)
PL (1) PL3324932T3 (es)
PT (1) PT3324932T (es)
RS (1) RS61607B1 (es)
SI (1) SI3324932T1 (es)
SM (1) SMT202100196T1 (es)
TW (1) TWI732773B (es)
WO (1) WO2017015552A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3324932T3 (da) * 2015-07-22 2021-04-06 Nitto Denko Corp Sammensætninger og fremgangsmåder for nanopartikel lyofile former
US20210069121A1 (en) 2017-12-12 2021-03-11 Lead Biotherapeutics Ltd Solid lipid nanoparticle for intracellular release of active substances and method for production the same
CN108813619A (zh) * 2018-07-19 2018-11-16 广州市汉廷食品有限公司 一种无公害食品添加剂及其制备工艺
IL281135B2 (en) 2018-09-28 2024-12-01 Nutcracker Therapeutics Inc Tertiary amino lipidated cationic peptides for nucleic acid delivery
PT3880212T (pt) * 2018-11-16 2024-02-08 Nitto Denko Corp Formulação e métodos de administração de rna de interferência para tumores malignos
CN114727964A (zh) * 2019-09-26 2022-07-08 日油株式会社 脂质纳米粒子的冻干组合物
CA3173554A1 (en) * 2020-02-28 2021-09-02 Microcures, Inc. Fidgetin-like 2 as a target to enhance wound healing
WO2021216541A1 (en) * 2020-04-20 2021-10-28 Board Of Regents, The University Of Texas System Biologically active dry powder compositions and method of their manufacture and use
JP2023537609A (ja) * 2020-08-14 2023-09-04 アークトゥラス・セラピューティクス・インコーポレイテッド 脂質ナノ粒子を凍結乾燥する方法
TW202228652A (zh) 2020-10-02 2022-08-01 國立大學法人北海道大學 脂質奈米粒子
EP4416287A1 (en) 2021-10-14 2024-08-21 Hemoshear Therapeutics, Inc. Compositions and methods of treating diseases associated with bile acid transporter
KR102712873B1 (ko) * 2021-12-20 2024-10-04 고려자연식품(주) 과일향기 포집을 위한 나노 지질 전달체 제조와 분말화 방법
CN116643056B (zh) * 2022-02-15 2025-02-18 厦门万泰凯瑞生物技术有限公司 促甲状腺激素受体复合物、试剂盒、制备方法和用途
US20240254485A1 (en) 2023-01-13 2024-08-01 Hemoshear Therapeutics, Inc. Sirnas targeting slc10a1 transcripts, compositions and uses thereof
WO2025015189A1 (en) * 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537683A (en) 1982-02-01 1985-08-27 Rohm And Haas Company Trihalomethane precursor removal using ion exchange emulsions
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4927571A (en) 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
BR122012021252B8 (pt) * 2002-09-06 2021-05-25 Cerulean Pharma Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
CA2528411C (en) 2003-06-04 2012-09-04 Georgetown University Method for improving stability and shelf-life of liposome complexes
CA2584583A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
US20060159737A1 (en) * 2004-11-19 2006-07-20 Steffen Panzner Pharmaceutical compositions for local administration
US8263117B2 (en) * 2007-02-09 2012-09-11 National University Corporation NARA Institute of Science and Technology C70-containing liposome, method for producing the same, and use of the same
US8357401B2 (en) * 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
CN102018672B (zh) * 2010-11-29 2013-09-18 广州朗圣药业有限公司 一种水溶性药物的脂质体冻干组合物及其制备方法
CN103748078B (zh) * 2011-06-08 2016-11-09 夏尔人类遗传性治疗公司 可裂解脂质
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
CN104114156A (zh) 2011-10-21 2014-10-22 切拉托尔制药公司 冻干脂质体
KR102046968B1 (ko) * 2011-11-04 2019-12-02 닛토덴코 가부시키가이샤 지질-핵산입자를 멸균생성을 위한 단일 용도 시스템
US9579338B2 (en) * 2011-11-04 2017-02-28 Nitto Denko Corporation Method of producing lipid nanoparticles for drug delivery
RS54513B1 (sr) 2012-03-28 2016-06-30 Discovery Laboratories, Inc. Liofilizacija sintetičkog lipozomalnog plućnog surfaktanta
CA2868030C (en) * 2012-03-29 2021-05-25 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
TR201816986T4 (tr) 2012-06-08 2019-01-21 Nitto Denko Corp Terapötik ajan iletim formülasyonlarına yönelik lipitler.
US20140271815A1 (en) 2013-03-15 2014-09-18 Aryo Sorayya Heat-and freeze-stable vaccines and methods of making and using same
DK3324932T3 (da) * 2015-07-22 2021-04-06 Nitto Denko Corp Sammensætninger og fremgangsmåder for nanopartikel lyofile former

Also Published As

Publication number Publication date
PT3324932T (pt) 2021-04-06
KR20180030698A (ko) 2018-03-23
CA2992849A1 (en) 2017-01-26
CN113679689A (zh) 2021-11-23
CA2992849C (en) 2023-06-13
WO2017015552A1 (en) 2017-01-26
US12311055B2 (en) 2025-05-27
LT3324932T (lt) 2021-04-26
IL288342B2 (en) 2024-02-01
CN113679689B (zh) 2023-09-01
AU2016297153B2 (en) 2021-02-25
JP2021119161A (ja) 2021-08-12
US20240000710A1 (en) 2024-01-04
RS61607B1 (sr) 2021-04-29
EA201890367A1 (ru) 2018-06-29
EP3324932A1 (en) 2018-05-30
IL288342A (en) 2022-01-01
CY1123984T1 (el) 2022-05-27
EA035761B1 (ru) 2020-08-06
MX373982B (es) 2020-07-15
PL3324932T3 (pl) 2021-07-05
JP6875373B2 (ja) 2021-05-26
HUE053990T2 (hu) 2021-08-30
JP7268079B2 (ja) 2023-05-02
DK3324932T3 (da) 2021-04-06
IL257029B (en) 2021-12-01
HRP20210523T1 (hr) 2021-05-14
US10300018B2 (en) 2019-05-28
BR112018001178A2 (pt) 2018-09-11
IL288342B1 (en) 2023-10-01
CN108024957A (zh) 2018-05-11
AU2016297153A1 (en) 2018-03-01
IL257029A (en) 2018-03-29
TW201717914A (zh) 2017-06-01
ES2862191T3 (es) 2021-10-07
SI3324932T1 (sl) 2021-07-30
SMT202100196T1 (it) 2021-05-07
KR102716928B1 (ko) 2024-10-11
US20190231695A1 (en) 2019-08-01
EP3324932A4 (en) 2019-03-06
EP3324932B1 (en) 2021-03-10
US20170020819A1 (en) 2017-01-26
TWI732773B (zh) 2021-07-11
US11737982B2 (en) 2023-08-29
CN108024957B (zh) 2021-08-24
JP2018521083A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
MX2018000891A (es) Composiciones y metodos para formas de liofilos de nanoparticulas.
AR113031A1 (es) Composiciones de nanopartículas lipídicas (lnp) que comprende arn
MX2017016088A (es) Oligonucleotidos multi-conjugados definidos.
EA201991369A1 (ru) Модифицированные направляющие рнк
EP3662913A4 (en) Nucleic-acid-containing lipid nanoparticles
MX2020003841A (es) Métodos y composiciones para la producción de nucleósido trifosfatos y ácidos ribonucleicos.
SMT201600325B (it) Alifani, ciclofani, eterafani, eterofani, etero-eterafani e metalloceni sostituiti utili per il trattamento di infezioni da hcv
MA45188A (fr) Oligonucléotides, compositions et méthodes associées
SI3445850T1 (sl) Postopki za zagotavljanje enoverižne RNA
PT3294325T (pt) Intensificar o efeito de células t manipuladas por car por meio da vacinação de ácidos nucleicos
MX382901B (es) Composiciones de angiotensinogeno (agt) arni y métodos de uso de las mismas.
MX2016000019A (es) (arnip) gen especifico relacionado con las enfermedades respiratorias, (arnip) que contiene la estructura arn oligo helicoidal, composicion que contiene la misma para prevencion o tratamiento de las enfermedades respiratorias.
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
MX2016012893A (es) Sustancias terapéuticas combinadas supramoleculares.
PT2755473T (pt) Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
MX394576B (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn)
WO2015003113A3 (en) Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna
WO2011116152A3 (en) Delivery of agents using interfering nanoparticles
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
MX2016004285A (es) Tratamiento de tumor por combinacion con minicelulas dirigidas a ligando, biespecificas, cargadas con farmacos e interferon-gamma.
BR112018003154A2 (pt) soluções de glicosídeo de esteviol
CR20160195A (es) Composiciones y métodos para inhibir la expresión del gen alas 1
DK3294756T3 (da) Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
WO2016183009A3 (en) Methods and compositions for the specific inhibition of antithrombin 3 (at3) by double-stranded rna

Legal Events

Date Code Title Description
FG Grant or registration